Nantes, France

Emmanuel Coron

This inventor holds 1 USPTO granted patent. Top assignees: Chu De Nantes—centre Hospitalier Universitaire De Nantes, National Institute of Health and Medical Research, The University of Nantes. Active years: 2023.


% Patents Active = 100.0

Average Co-Inventor Count = 3.0

ph-index = 1


Company Filing History:


Years Active: 2023

Loading Chart...
1 patent (USPTO):Explore Patents

Title: Emmanuel Coron: Innovator in Chronic Inflammatory Intestinal Disease Diagnosis

Introduction

Emmanuel Coron is a notable inventor based in Nantes, France. He has made significant contributions to the field of medical diagnostics, particularly concerning chronic inflammatory intestinal diseases. His innovative work has the potential to improve the lives of many individuals suffering from these conditions.

Latest Patents

Emmanuel Coron holds a patent for a process aimed at diagnosing chronic inflammatory intestinal diseases. This patent includes methods for quantifying changes in the intestinal mucosa caused by such diseases. It also outlines an ex vivo process for diagnosing these conditions and differentiating between Crohn's disease and ulcerative colitis.

Career Highlights

Throughout his career, Emmanuel has been associated with esteemed institutions such as the University of Nantes and the Centre Hospitalier Universitaire de Nantes. His work in these organizations has allowed him to advance his research and contribute to the medical community.

Collaborations

Emmanuel has collaborated with notable colleagues, including Jérémy Brégeon and Michel Neunlist. These partnerships have enriched his research and fostered innovation in the field of intestinal disease diagnostics.

Conclusion

Emmanuel Coron's contributions to the diagnosis of chronic inflammatory intestinal diseases highlight his role as an important inventor in the medical field. His work continues to pave the way for advancements in patient care and diagnostic processes.

Profile summary based on public USPTO records.
Please report any incorrect information to [email protected]
Loading…